FAK Inhibitors Market Growing Rapidly, Estimates DelveInsight | Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed are Expected to Contribute to Growth

News provided by

Apr 25, 2023, 11:00 ET

The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety profile to treat a wide array of cancers. Key players, such as InxMed, Verastem, GlaxoSmithKline, Merck, and others, are involved in developing novel therapies for indications

LAS VEGAS, April 25, 2023 /PRNewswire/ -- DelveInsight's FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the FAK Inhibitors Market Report

DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period (2019–2032).
Globally, leading FAK inhibitors companies such as Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others are developing novel FAK inhibitors that can be available in the FAK inhibitors market in the coming years.
Some key FAK inhibitors include VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others.
Several FAK inhibitors are awaiting approval, while some FAK inhibitors are in the advanced stages of development.

Discover which FAK inhibitors are expected to grab the major FAK inhibitors market share @ FAK Inhibitors Market Report

FAK Inhibitors Overview

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed and activated in both adult and pediatric malignancies, where it plays critical roles in the regulation of pathogenesis and progression of the malignant phenotype. FAK operates in cancer in two ways: as a kinase activity in the cytoplasm, which is primarily dependent on integrin signaling, and as a scaffolding activity in the nucleus, which is accomplished through networking with various gene expressions. The FAK gene, also known as protein tyrosine kinase 2 (PTK2), is located on human chromosome 8q24.3 and encodes the FAK protein, which is found in many different types of cells and is mostly found in the plasma membrane and cytoplasm. FAK is classified into three domains: N-terminal FERM, core kinase, and C-terminal domains. The FAK FERM region is non-catalytic, and a similar FERM motif may be found in Janus kinase (JAK), another tyrosine kinase.

Learn more about FAK inhibitors for cancer therapy @ FAK Inhibitors

FAK Inhibitors Market Insights

Despite decades of cytotoxic chemotherapy experience, no drug or combination of agents has yet to cure cancer. Targeting molecular therapies to those molecules and pathways that promote cancer progression has become an increasingly appealing option as the biological underpinnings of carcinogenesis are better known. The FDA recently approved tebentafusp (Kimmtrak) for the treatment of selected individuals with uveal melanoma, as well as olaparib for the maintenance therapy of adult patients with deleterious or suspected detrimental germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma. The NICE has authorized Niraparib for women with advanced ovarian cancer.

The FDA approved tebentafusp, a bispecific fusion protein, in January 2022. It works by allowing immune cells to get near enough to cancer cells to attack them. The clinical trial assessed the drug as an initial treatment for persons with metastatic uveal melanoma. According to the permission, tebentafusp can be used in persons whose cells contain a protein called HLA-A*02:01 and whose cancer cannot be removed surgically or has migrated to other parts of their body. Niraparib (Zejula, GlaxoSmithKline) is approved for use in the United Kingdom as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages 3 and 4) high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in response following completion of first-line platinum-based chemotherapy.

The Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) in December 2019 for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, and whose disease has not progressed after at least 16 weeks of a first-line platinum-based chemotherapy regimen.

To know more about FAK inhibitors, visit @ FAK Inhibitors Analysis

Key FAK Inhibitors Drugs and Companies

VS-6766 + defactinib: Verastem, Inc.
Defactinib: Verastem, Inc.
FAK Inhibitor GSK2256098: GlaxoSmithKline
VS-6063: Verastem, Inc.
Pembrolizumab: Merck Sharp & Dohme LLC
PF-04554878: Pfizer
IN10018: InxMed
KIMMTRAK (tebentafusp): Immunocore
ZEJULA (niraparib): GlaxoSmithKline
LYNPARZA (olaparib): AstraZeneca
AVASTIN (bevacizumab): Genentech

Learn more about the FDA-approved FAK inhibitors @ Approved FAK Inhibitors

FAK Inhibitors Market Dynamics

The dynamics of the FAK inhibitors market are expected to evolve as leading pharma and biotech companies around the world work hard to develop novel FAK choices with convenient RoA and a better safety profile to treat a wide range of malignancies. Furthermore, the FAK inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the FAK inhibitors market in the 7MM.

However, several factors are impeding the growth of the FAK inhibitors market. Furthermore, the FAK inhibitors market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. Thus all these factors may cause a dip in the FAK inhibitors market growth in the coming year.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year	2019
Key FAK Inhibitors Companies	Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others
Key FAK Inhibitors Therapies	VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others

Scope of the FAK Inhibitors Market Report

Therapeutic Assessment: Current Marketed and Emerging FAK Inhibitors
FAK Inhibitors Market Dynamics: Attribute Analysis of Emerging FAK Inhibitors
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, FAK Inhibitors Market Access and Reimbursement

Discover more about FAK inhibitors in clinical development @ FAK Inhibitors in Clinical Trials

Table of Contents

1.	FAK Inhibitors Market Key Insights
2.	FAK Inhibitors Market Report Introduction
3.	FAK Inhibitors Market Overview at a Glance
4.	FAK Inhibitors Market Executive Summary
5.	Disease Background and Overview
6.	FAK Inhibitors Marketed Drugs
7.	FAK Inhibitors Emerging Drugs
8.	Seven Major FAK Inhibitors Market Analysis
9.	FAK Inhibitors Market Outlook
10.	Potential of Current and Emerging Therapies
11.	KOL Views
12.	FAK Inhibitors Market Drivers
13.	FAK Inhibitors Market Barriers
14.	Unmet Needs
15.	SWOT Analysis
16.	Appendix
17.	DelveInsight Capabilities
18.	Disclaimer
19.	About DelveInsight

Related Reports

PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

Other Trending Oncology Reports

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

LAG 3: A Promising Next-Generation Cancer Immunotherapy

ENHERTU's Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP